BiotechTube
Home/Pipeline/Perthera Report® Pancreatic Cancer Version

Perthera Report® Pancreatic Cancer Version

Pancreatic Cancer

CommercialActive

Key Facts

Indication
Pancreatic Cancer
Phase
Commercial
Status
Active
Company
Perthera

About Perthera

Perthera is a leader in AI-driven precision oncology, offering a comprehensive platform that integrates multi-omic testing results and patient history to match cancer patients with ranked therapy options. Its core product, the Perthera Report®, is used by oncologists to optimize treatment decisions and streamline clinical workflows, while its data pipeline supports real-world evidence generation and clinical trial matching. The company has established a significant footprint, with its platform reportedly used in 600 hospitals/clinics and by 10% of US medical oncologists, and it demonstrates strong clinical impact metrics, including a 2.4x improvement in progression-free survival for its patients.

View full company profile

Therapeutic Areas

Oncology

Other Pancreatic Cancer Drugs

DrugCompanyPhase
Ampligen® (rintatolimod)AIM ImmunoTechEarly Access Program
HBM9027Harbour BioMedPhase 1
Small-Molecule TherapeuticAIkido LabsPre-clinical
AHPBA IRE RegistryAngioDynamicsPost-Market Registry
SIMBs + ImmunotherapyAdvanced MicrobubblesPre-clinical
CLS-014CLS TherapeuticsPre-clinical
SOMA PlatformCoherence NeuroPre-clinical
NP-G2-044Novita PharmaceuticalsPhase 2a
Pritumumab (PTB)Nascent BiotechPhase II (Planned)
Pancreatic Cancer TestMosaique DiagnosticDevelopment
Iontophoretic SystemContinuity BiosciencesPre-clinical
Lixumistat (IM156)ImmunoMet TherapeuticsPhase 1b